Login Register Cart 0
Generic placeholder image

Current Molecular Pharmacology

Editor-in-Chief

ISSN (Print): 1874-4672
ISSN (Online): 1874-4702

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Prevalence of Hepatocellular Carcinoma in Men and the Contribution of Androgen and its Receptor in Pathogenesis and Therapy

Author(s): Nabil Mohie Abdel-Hamid* and Rawaa Muayad Al-Quzweny

Volume 16, Issue 5, 2023

Published on: 27 December, 2022

Article ID: e101022209750 Pages: 5

DOI: 10.2174/1874467215666221010092825

Price: $65

conference banner
Abstract

Background: Hepatocellular carcinoma (HCC) is a solid cancer with high predominance in males. Liver tissue of both genders has saturable specific oestrogen receptors. Androgen and its receptor (AR) have been suggested to contribute to the predominance in men. Anti-oestrogens, like tamoxifen may reduce the expression of oestrogen receptors, sustaining cellular in HCC. In vitro and human, studies confirmed that both testosterone and dihydrotestosterone (DHT) enhanced the growth and proliferation of hepatic normal and tumour cells. Although the activity of AR is escalated by the chemical induction of hepatocarcinogenesis; clinical trials with AR-targeted agents alone failed to generate survival benefits.

Purpose: This review will outline the possible pathophysiological mechanisms by which both androgen and AR contribute to hepatocarcinogenesis and to which extent this pathway can be responsible for the male prevalence and if they could be pharmacological targets in HCC management.

Conclusion: Influencing factors that seem to be responsible for male prevalence include testosterone, dihydrotestosterone and androgen receptors, as well as, proteomic deficiency of DNA packaging, nuclear proteins and homeostasis-related functional proteins. Understanding the reasons for males, rather than females the HCC prevalence may help in suggesting new approaches by improving the anti-AR therapies through co-targeting of AR and protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway.

Graphical Abstract

[1]
Society, A.C. What Is Liver Cancer?Available from, https://www.cancer.org/cancer/liver-cancer/about/what-is-liver-cancer.html
[2]
Blechacz, B.; Komuta, M.; Roskams, T.; Gores, G.J. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol., 2011, 8(9), 512-522.
[http://dx.doi.org/10.1038/nrgastro.2011.131] [PMID: 21808282]
[3]
Rujeerapaiboon, N.; Wetwittayakhlang, P. Primary hepatic angiosarcoma: A rare liver malignancy – varying manifestations but grave prognosis. Case Rep. Gastroenterol., 2020, 14(1), 137-149.
[http://dx.doi.org/10.1159/000506928] [PMID: 32355483]
[4]
Karahasanoglu, R.; Otcu, H.; Selcuk, T.; Ucar, A.; Kiris, A. Focal nodular hyperplasia vs. hemangioma: Computed tomography and magnetic resonance imaging findings. Ann. Hepatol., 2011, 10(2), 218-220.
[http://dx.doi.org/10.1016/S1665-2681(19)31572-8] [PMID: 21502685]
[5]
Dhanasekaran, R.; Limaye, A.; Cabrera, R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat. Med., 2012, 4, 19-37.
[PMID: 24367230]
[6]
Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 2010, 127(12), 2893-2917.
[http://dx.doi.org/10.1002/ijc.25516] [PMID: 21351269]
[7]
Watson, J.; Hydon, K.; Lodge, P. Primary and secondary liver tumours. InnovAiT, 2016, 9(8), 477-482.
[http://dx.doi.org/10.1177/1755738016653419]
[8]
Kanda, T.; Steele, R.; Ray, R.; Ray, R.B. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J. Virol., 2008, 82(22), 11066-11072.
[http://dx.doi.org/10.1128/JVI.01300-08] [PMID: 18768969]
[9]
Ries, L.A.; Harkins, D.; Krapcho, M. SEER cancer statistics review, , 1975.2003-2006.
[10]
Lepor, H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev. Urol., 2005, 7(S5), S3-S12.
[11]
Loblaw, DA.; Virgo, KS.; Nam, R. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. Am. Soc. Clinic. Oncolpractice Guide., 2007, 25, 1596-1605.
[12]
Naugler, W.E.; Sakurai, T.; Kim, S.; Maeda, S.; Kim, K.; Elsharkawy, A.M.; Karin, M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 2007, 317(5834), 121-124.
[http://dx.doi.org/10.1126/science.1140485] [PMID: 17615358]
[13]
Montella, M.; Crispo, A.; Giudice, A. HCC, diet and metabolic factors: Diet and HCC. Hepat. Mon., 2011, 11(3), 159-162.
[PMID: 22087137]
[14]
Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin., 2011, 61(2), 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[15]
Abou-Alfa, G.K. Sorafenib use in hepatocellular carcinoma: More questions than answers. Hepatology, 2014, 60(1), 15-18.
[http://dx.doi.org/10.1002/hep.27044] [PMID: 24493250]
[16]
Giannitrapani, L.; Soresi, M.; La Spada, E.; Cervello, M.; D’Alessandro, N.; Montalto, G. Sex hormones and risk of liver tumor. Ann. N. Y. Acad. Sci., 2006, 1089(1), 228-236.
[http://dx.doi.org/10.1196/annals.1386.044] [PMID: 17261770]
[17]
Chan, A.C.Y.; Chok, K.S.; Yuen, W.K.; Chan, S.C.; Poon, R.T.; Lo, C.M.; Fan, S.T. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch. Surg., 2011, 146(6), 675-681.
[http://dx.doi.org/10.1001/archsurg.2011.125] [PMID: 21690443]
[18]
Kalra, M.; Mayes, J.; Assefa, S.; Kaul, A.K.; Kaul, R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J. Gastroenterol., 2008, 14(39), 5945-5961.
[http://dx.doi.org/10.3748/wjg.14.5945] [PMID: 18932272]
[19]
Lai, K.P.; Yamashita, S.; Huang, C.K.; Yeh, S.; Chang, C. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro‐inflammatory cytokines/chemokines. EMBO Mol. Med., 2012, 4(8), 791-807.
[http://dx.doi.org/10.1002/emmm.201101140] [PMID: 22745041]
[20]
Maheshwari, A.; Thuluvath, P.J. Endocrine diseases and the liver. Clin. Liver Dis., 2011, 15(1), 55-67.
[http://dx.doi.org/10.1016/j.cld.2010.09.008] [PMID: 21111993]
[21]
Ruggieri, A.; Barbati, C.; Malorni, W. Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int. J. Cancer, 2010, 127(3), 499-504.
[http://dx.doi.org/10.1002/ijc.25298] [PMID: 20201099]
[22]
Yeh, S.H.; Chen, P.J. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology, 2010, 78(S1), 172-179.
[http://dx.doi.org/10.1159/000315247] [PMID: 20616601]
[23]
Liang, T.; He, Y.; Mo, S.; Chen, Z.; Liao, X.; Zhou, X.; Yang, C.; Zhao, S.; Han, C.; Zhu, G.; Su, H.; Ye, X.; Peng, T. Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy. Ann. Hepatol., 2022, 27(3)100695
[http://dx.doi.org/10.1016/j.aohep.2022.100695] [PMID: 35257933]
[24]
Wu, E.M.; Wong, L.L.; Hernandez, B.Y.; Ji, J.F.; Jia, W.; Kwee, S.A.; Kalathil, S. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res., 2018, 4(10), 66.
[http://dx.doi.org/10.20517/2394-5079.2018.87] [PMID: 30687780]
[25]
liu; Liang, X.; Liu, X.; Deng, Z.; Ma, L. Impact of gender on the prognosis of patients with hepatocellular carcinoma after palliative therapy. Eurasian J. Med. Oncol., 2021, 5, 222-227.
[http://dx.doi.org/10.14744/ejmo.2021.19181]
[26]
Rania Hefaiedh, R.E.; Romdhane, H.; Arfa, N.; Ben Nejma, H.; Belhadj, N.; Gharbi, L.; Khalfallah, T. Gender difference in patients with hepatocellular carcinoma. Tunis. Med., 2013, 91, 432-435.
[27]
Manieri, E.; Herrera-Melle, L.; Mora, A.; Tomás-Loba, A.; Leiva-Vega, L.; Fernández, D.I.; Rodríguez, E.; Morán, L.; Hernández-Cosido, L.; Torres, J.L.; Seoane, L.M.; Cubero, F.J.; Marcos, M.; Sabio, G. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J. Exp. Med., 2019, 216(5), 1108-1119.
[http://dx.doi.org/10.1084/jem.20181288] [PMID: 30944152]
[28]
Chen, C.L.; Kuo, M.J.; Yen, A.M.F.; Yang, W.S.; Kao, J.H.; Chen, P.J.; Chen, H.H. Gender difference in the association between metabolic factors and hepatocellular carcinoma. JNCI Cancer Spectr., 2020, 4(5)pkaa036
[http://dx.doi.org/10.1093/jncics/pkaa036] [PMID: 33134821]
[29]
Rong, Z.; Fan, T.; Li, H.; Li, J.; Wang, K.; Wang, X.; Dong, J.; Chen, J.; Wang, F.; Wang, J.; Wang, A. Differential proteomic analysis of gender-dependent hepatic tumorigenesis in Hras12V transgenic mice. Mol. Cell. Proteomics, 2017, 16(8), 1475-1490.
[http://dx.doi.org/10.1074/mcp.M116.065474] [PMID: 28512230]
[30]
Pignata, S.; Daniele, B.; Gallo, C.; De Vivo, R.; Monfardini, S.; Perrone, F. Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit? Eur. J. Cancer, 1998, 34(1), 25-32.
[http://dx.doi.org/10.1016/S0959-8049(97)00317-1] [PMID: 9624234]
[31]
Ouyang, X.; Feng, L.; Liu, G.; Yao, L.; Wang, Z.; Liu, S.; Xiao, Y.; Zhang, G. Androgen receptor (AR) decreases HCC cells migration and invasion via miR-325/ACP5 signaling. J. Cancer, 2021, 12, 1915-1925.
[32]
Ma, W.L.; Hsu, C.L.; Yeh, C.C.; Wu, M.H.; Huang, C.K.; Jeng, L.B.; Hung, Y.C.; Lin, T.Y.; Yeh, S.; Chang, C. Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. Hepatology, 2012, 56(1), 176-185.
[http://dx.doi.org/10.1002/hep.25644] [PMID: 22318717]
[33]
Eder, I.E.; Culig, Z.; Putz, T.; Nessler-Menardi, C.; Bartsch, G.; Klocker, H. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur. Urol., 2001, 40(3), 241-251.
[http://dx.doi.org/10.1159/000049782] [PMID: 11684838]
[34]
Kanda, T.; Takahashi, K.; Nakamura, M.; Nakamoto, S.; Wu, S.; Haga, Y.; Sasaki, R.; Jiang, X.; Yokosuka, O. Androgen receptor could be a potential therapeutic target in patients with advanced hepatocellular carcinoma. Cancers, 2017, 9(12), 43.
[http://dx.doi.org/10.3390/cancers9050043] [PMID: 28475115]
[35]
Zhang, H.; Spencer, K.; Burley, S.K.; Zheng, X.F.S. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov. Today, 2021, 26(6), 1539-1546.
[http://dx.doi.org/10.1016/j.drudis.2021.02.001] [PMID: 33561464]
[36]
Zhang, H.; Li, X.X.; Yang, Y.; Zhang, Y.; Wang, H.Y.; Zheng, X.F.S. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology, 2018, 67(6), 2271-2286.
[http://dx.doi.org/10.1002/hep.29715] [PMID: 29220539]
[37]
Helms, TH.; Mullins, RD.; Thomas-Ahner, J.M. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks. Sci. Report, 2021, 11, 1-16.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy